Advertisement
Advertisement
U.S. Markets close in 4 hrs 48 mins
Advertisement
Advertisement
Advertisement
Advertisement

LAVA Therapeutics N.V. (LVTX)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
3.9300-0.1500 (-3.68%)
As of 10:52AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.0800
Open3.8600
Bid3.9300 x 800
Ask3.9800 x 800
Day's Range3.7700 - 4.0799
52 Week Range2.2800 - 8.3800
Volume66,518
Avg. Volume790,665
Market Cap101.298M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.8670
Earnings DateNov 14, 2022 - Nov 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.72
  • Business Wire

    Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors

    BOTHELL, Wash. & UTRECHT, Netherlands & PHILADELPHIA, September 26, 2022--Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers, today announced an exclusive license agreement in which Seagen will work to develop, manufacture and commercialize LAVA-1223. LAVA-1223 is an

  • GlobeNewswire

    LAVA Therapeutics Provides Business Update and Reports Second Quarter Financial Results

    Initial Phase 1/2a clinical findings for LAVA-051 in patients with chronic lymphocytic leukemia and multiple myeloma patients demonstrated encouraging anti-tumor activity and safety profile; on track to report additional clinical data in fourth quarter 2022 Enrollment continuing in LAVA-1207 Phase 1/2a trial in metastatic castration-resistant prostate cancer Cash and investments of $110.7 million as of June 30, 2022, providing approximately two years of cash runway Appointed James Noble and Jay

  • GlobeNewswire

    LAVA Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

    UTRECHT, The Netherlands and PHILADELPHIA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will present in a virtual format at the H.C. Wainwright 24th Annual Global Investment Conference being held

Advertisement
Advertisement